Swiss - Delayed Quote CHF

Relief Therapeutics Holding SA (RLF.SW)

2.1600

-0.0200

(-0.92%)

At close: May 9 at 5:31:16 PM GMT+2

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and ...

ACCESS Newswire 30 days ago

RLFTF

RLFTY
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet ...

ACCESS Newswire 2 months ago

RLFTF

RLFTY
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

RELIEF THERAPEUTICS Holding SA(SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the ...

ACCESS Newswire 2 months ago

RLFTF

RLFTY
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale ...

ACCESS Newswire 3 months ago

RLFTF

RLFTY
Relief Therapeutics Provides Update on Potential Transaction with Renexxion

GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 4 months ago

RLFTF

RLFTY
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU Patients Results Expected to Promote Awareness and Adoption of PKU GOLIKE ® GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2024 /RELIEF THERAPEUTICS Holding SA ...

ACCESS Newswire 4 months ago

RLFTF

RLFTY
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2024 /RELIEF THERAPEUTICS Holding SA(SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical ...

ACCESS Newswire 4 months ago

RLFTF

RLFTY
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 5 months ago

RLFTF

RLFTY
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 6 months ago

RLFTF

RLFTY
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

GENEVA, SWITZARLAND / ACCESSWIRE / October 29, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 6 months ago

RLFTF

RLFTY
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

New Study Results Indicate Superior Absorption of RLF-OD032 in Fasted State Compared to KUVAN®, Potentially Enabling Flexible Dosing Options GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ...

ACCESS Newswire 6 months ago

RLFTF

RLFTY
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 6 months ago

RLFTF

RLFTY
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 6 months ago

RLFTF

RLFTY
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

GENEVA, SWITZERLAND / ACCESSWIRE / October 4, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 7 months ago

RLFTF

RLFTY
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

GENEVA, SWITZERLAND / ACCESSWIRE / September 23, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 7 months ago

RLFTF

RLFTY
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 7 months ago

RLFTF

RLFTY
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...

ACCESS Newswire 8 months ago

RLFTF

RLFTY
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined operations and CHF 15.1 million cash reserves expected ...

ACCESS Newswire 8 months ago

RLFTF

RLFTY
Relief Therapeutics Secures up to $11 Million from Royalty Sales

Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical ...

ACCESS Newswire 8 months ago

RLFTF

RLFTY
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select ...

ACCESS Newswire 10 months ago

RLFTF

RLFTY

Performance Overview

Return	RLF.SW	MSCI WORLD (^990100-USD-STRD)
YTD	-48.69%	-0.19%
1-Year	+77.05%	+9.31%
3-Year	-90.44%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Relief Therapeutics Holding SA (RLF.SW)

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Secures up to $11 Million from Royalty Sales

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

Performance Overview